View of Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial

Return to Article Details Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial Download Download PDF